Skip to main content
SpringerLink
Log in

Genetics of Redox Systems and Their Relationship with Cardiovascular Disease

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

As atherosclerosis is still one of the major causes of death in Western populations, it is important to identify those individuals who are at increased risk for the disease so that aggressive treatment may be administered as early as possible. Following the understanding that oxidative stress has a pivotal role in the development and progression of atherosclerosis, many polymorphisms in genes that are related to redox systems were examined for their association with increased risk for cardiovascular disease (CVD). Although many polymorphisms were studied, only a handful showed consistent relevance to CVD in different trials. This article focuses on six of these polymorphisms, examining their effect on the risk for CVD as well as their effect on protein expression and function. Reports regarding pharmacogenetic implications of these polymorphisms, where such exist, are discussed as well.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104(4):503–16.

    Article  PubMed  CAS  Google Scholar 

  2. Kondo T, Hirose M, Kageyama K. Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscler Thromb. 2009;16(5):532–8.

    PubMed  CAS  Google Scholar 

  3. Farbstein D, Levy AP. The genetics of vascular complications in diabetes mellitus. Cardiol Clin. 2010;28(3):477–96.

    Article  PubMed  Google Scholar 

  4. Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem. 1993;268(23):17478–88.

    PubMed  CAS  Google Scholar 

  5. Dudzinski DM, Michel T. Life history of eNOS: partners and pathways. Cardiovasc Res. 2007;75(2):247–60.

    Article  PubMed  CAS  Google Scholar 

  6. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res. 1999;43(3):521–31.

    Article  PubMed  CAS  Google Scholar 

  7. Napoli C, Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharm Res. 2009;32(8):1103–8.

    Article  PubMed  CAS  Google Scholar 

  8. Napoli C, Ignarro LJ. Polymorphisms in endothelial nitric oxide synthase and carotid artery atherosclerosis. J Clin Pathol. 2007;60(4):341–4.

    Article  PubMed  CAS  Google Scholar 

  9. McDonald DM, Alp NJ, Channon KM. Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells. Pharmacogenetics. 2004;14(12):831–9.

    Article  PubMed  CAS  Google Scholar 

  10. Naber CK, Baumgart D, Altmann C, Siffert W, Erbel R, Heusch G. eNOS 894 T allele and coronary blood flow at rest and during adenosine-induced hyperemia. Am J Physiol. 2001;281(5):H1908–1912.

    CAS  Google Scholar 

  11. Rossi GP, Taddei S, Virdis A, Cavallin M, Ghiadoni L, Favilla S, et al. The T-786 C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol. 2003;41(6):938–45.

    Article  PubMed  CAS  Google Scholar 

  12. Gulec S, Karabulut H, Ozdemir AO, Ozdol C, Turhan S, Altin T, et al. Glu298Asp polymorphism of the eNOS gene is associated with coronary collateral development. Atherosclerosis. 2008;198(2):354–9.

    Article  PubMed  CAS  Google Scholar 

  13. Miyamoto Y, Saito Y, Nakayama M, Shimasaki Y, Yoshimura T, Yoshimura M, et al. Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786 T– > C mutation associated with coronary spastic angina. Hum Mol Genet. 2000;9(18):2629–37.

    Article  PubMed  CAS  Google Scholar 

  14. Wang XL, Sim AS, Wang MX, Murrell GA, Trudinger B, Wang J. Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett. 2000;471(1):45–50.

    Article  PubMed  CAS  Google Scholar 

  15. Jeerooburkhan N, Jones LC, Bujac S, Cooper JA, Miller GJ, Vallance P, et al. Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease. Hypertension. 2001;38(5):1054–61.

    Article  PubMed  CAS  Google Scholar 

  16. Li J, Wu X, Li X, Feng G, He L, Shi Y. The endothelial nitric oxide synthase gene is associated with coronary artery disease: a meta-analysis. Cardiology. 2010;116(4):271–8.

    Article  PubMed  CAS  Google Scholar 

  17. Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol. 2006;164(10):921–35.

    Article  PubMed  Google Scholar 

  18. Comhair SA, Erzurum SC. The regulation and role of extracellular glutathione peroxidase. Antioxid Redox Signal. 2005;7(1–2):72–9.

    Article  PubMed  CAS  Google Scholar 

  19. • Margis R, Dunand C, Teixeira FK, Margis-Pinheiro M: Glutathione peroxidase family - an evolutionary overview. FEBS J 2008, 275(15):3959–3970. This is an excellent review of the glutathione peroxidase family of proteins and their functions.

  20. Voetsch B, Loscalzo J. Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol. 2004;24(2):216–29.

    Article  PubMed  CAS  Google Scholar 

  21. Voetsch B, Jin RC, Bierl C, Benke KS, Kenet G, Simioni P, et al. Promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene: a novel risk factor for arterial ischemic stroke among young adults and children. Stroke. 2007;38(1):41–9.

    Article  PubMed  CAS  Google Scholar 

  22. Kenet G, Freedman J, Shenkman B, Regina E, Brok-Simoni F, Holzman F, et al. Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. Arterioscler Thromb Vasc Biol. 1999;19(8):2017–23.

    PubMed  CAS  Google Scholar 

  23. • Voetsch B, Jin RC, Bierl C, Deus-Silva L, Camargo EC, Annichino-Bizacchi JM, Handy DE, Loscalzo J: Role of promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene as a risk factor for cerebral venous thrombosis. Stroke 2008, 39(2):303–307. This article demonstrates the importance of glutathione peroxidase polymorphism in stroke risk.

  24. Lei XG, Cheng WH, McClung JP. Metabolic regulation and function of glutathione peroxidase-1. Annu Rev Nutr. 2007;27:41–61.

    Article  PubMed  CAS  Google Scholar 

  25. Hamanishi T, Furuta H, Kato H, Doi A, Tamai M, Shimomura H, et al. Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in japanese type 2 diabetic patients. Diabetes. 2004;53(9):2455–60.

    Article  PubMed  CAS  Google Scholar 

  26. Nemoto M, Nishimura R, Sasaki T, Hiki Y, Miyashita Y, Nishioka M, et al. Genetic association of glutathione peroxidase-1 with coronary artery calcification in type 2 diabetes: a case control study with multi-slice computed tomography. Cardiovasc Diabetol. 2007;6:23.

    Article  PubMed  Google Scholar 

  27. Winter JP, Gong Y, Grant PJ, Wild CP. Glutathione peroxidase 1 genotype is associated with an increased risk of coronary artery disease. Coron Artery Dis. 2003;14(2):149–53.

    Article  PubMed  Google Scholar 

  28. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med. 2003;349(17):1605–13.

    Article  PubMed  CAS  Google Scholar 

  29. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem. 1990;1(5):228–37.

    Article  PubMed  CAS  Google Scholar 

  30. Jakubowski H. The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J Physiol Pharmacol. 2008;59 Suppl 9:155–67.

    PubMed  Google Scholar 

  31. Obeid R, Herrmann W. Homocysteine and lipids: S-adenosyl methionine as a key intermediate. FEBS Lett. 2009;583(8):1215–25.

    Article  PubMed  CAS  Google Scholar 

  32. Nygard O, Vollset SE, Refsum H, Brattstrom L, Ueland PM. Total homocysteine and cardiovascular disease. J Intern Med. 1999;246(5):425–54.

    Article  PubMed  CAS  Google Scholar 

  33. Kerkeni M, Tnani M, Chuniaud L, Miled A, Maaroufi K, Trivin F. Comparative study on in vitro effects of homocysteine thiolactone and homocysteine on HUVEC cells: evidence for a stronger proapoptotic and proinflammative homocysteine thiolactone. Mol Cell Biochem. 2006;291(1–2):119–26.

    Article  PubMed  CAS  Google Scholar 

  34. Chang PY, Lu SC, Lee CM, Chen YJ, Dugan TA, Huang WH, et al. Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation. Circ Res. 2008;102(8):933–41.

    Article  PubMed  CAS  Google Scholar 

  35. Tsai JC, Wang H, Perrella MA, Yoshizumi M, Sibinga NE, Tan LC, et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Investig. 1996;97(1):146–53.

    Article  PubMed  CAS  Google Scholar 

  36. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56(1):111–28.

    PubMed  CAS  Google Scholar 

  37. Van Guelpen B, Hultdin J, Johansson I, Witthoft C, Weinehall L, Eliasson M, et al. Plasma folate and total homocysteine levels are associated with the risk of myocardial infarction, independently of each other and of renal function. J Intern Med. 2009;266(2):182–95.

    Article  PubMed  Google Scholar 

  38. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. Jama. 2008;299(17):2027–36.

    Article  PubMed  CAS  Google Scholar 

  39. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567–77.

    Article  PubMed  CAS  Google Scholar 

  40. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369(9576):1876–82.

    Article  PubMed  CAS  Google Scholar 

  41. Lewis SJ, Ebrahim S, Davey Smith G: Meta-analysis of MTHFR 677 C- > T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ (Clinical research ed 2005, 331(7524):1053.

    Google Scholar 

  42. • Shih DM, Lusis AJ: The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Current opinion in lipidology 2009, 20(4):288–292. This is an excellent review of paraoxonase biology and its relationship to cardiovascular disease.

  43. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005;46(6):1239–47.

    Article  PubMed  CAS  Google Scholar 

  44. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21(4):473–80.

    PubMed  CAS  Google Scholar 

  45. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286(1–2):152–4.

    Article  PubMed  CAS  Google Scholar 

  46. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Investig. 1995;96(6):2882–91.

    Article  PubMed  CAS  Google Scholar 

  47. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394(6690):284–7.

    Article  PubMed  CAS  Google Scholar 

  48. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000;275(23):17527–35.

    Article  PubMed  CAS  Google Scholar 

  49. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002;106(4):484–90.

    Article  PubMed  CAS  Google Scholar 

  50. Deakin S, Leviev I, Brulhart-Meynet MC, James RW. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. Biochem J. 2003;372(Pt 2):643–9.

    Article  PubMed  CAS  Google Scholar 

  51. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet. 2004;363(9410):689–95.

    Article  PubMed  CAS  Google Scholar 

  52. Najafi M, Gohari LH, Firoozrai M. Paraoxonase 1 gene promoter polymorphisms are associated with the extent of stenosis in coronary arteries. Thromb Res. 2009;123(3):503–10.

    Article  PubMed  CAS  Google Scholar 

  53. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res. 2006;47(11):2492–502.

    Article  PubMed  CAS  Google Scholar 

  54. • Dahabreh IJ, Kitsios GD, Kent DM, Trikalinos TA: Paraoxonase 1 polymorphisms and ischemic stroke risk: A systematic review and meta-analysis. Genet Med 2010, 12(10):606–615. This article is a recent comprehensive meta-analysis of paraoxonase polymorphisms and their relationship.

  55. Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol. 2003;23(8):1465–71.

    Article  PubMed  CAS  Google Scholar 

  56. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. Jama. 2008;299(11):1265–76.

    Article  PubMed  CAS  Google Scholar 

  57. Miao L, St Clair DK. Regulation of superoxide dismutase genes: implications in disease. Free Radic Biol Med. 2009;47(4):344–56.

    Article  PubMed  CAS  Google Scholar 

  58. Lebovitz RM, Zhang H, Vogel H, Cartwright Jr J, Dionne L, Lu N, et al. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci USA. 1996;93(18):9782–7.

    Article  PubMed  CAS  Google Scholar 

  59. Jones DA, Prior SL, Tang TS, Bain SC, Hurel SJ, Humphries SE, Stephens JW: Association between the rs4880 superoxide dismutase 2 (C > T) gene variant and coronary heart disease in diabetes mellitus. Diabetes Res Clin Pract 2010.

  60. Mollsten A, Marklund SL, Wessman M, Svensson M, Forsblom C, Parkkonen M, et al. A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. Diabetes. 2007;56(1):265–9.

    Article  PubMed  Google Scholar 

  61. Fujimoto H, Kobayashi H, Ogasawara K, Yamakado M, Ohno M. Association of the manganese superoxide dismutase polymorphism with vasospastic angina pectoris. J Cardiol. 2010;55(2):205–10.

    Article  PubMed  Google Scholar 

  62. Fujimoto H, Taguchi J, Imai Y, Ayabe S, Hashimoto H, Kobayashi H, et al. Manganese superoxide dismutase polymorphism affects the oxidized low-density lipoprotein-induced apoptosis of macrophages and coronary artery disease. Eur Heart J. 2008;29(10):1267–74.

    Article  PubMed  CAS  Google Scholar 

  63. Bowman BH, Kurosky A: Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Advances in human genetics 1982, 12:189–261, 453–184.

  64. • Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R, Kalet-Litman S, Anbinder Y, Lache O, Nakhoul FM, Asaf R et al: Haptoglobin: Basic and Clinical Aspects. Antioxidants & redox signaling 2009. This is an excellent summary of work showing basic mechanisms and clinical studies showing the importance of the haptoglobin polymorphism in predicting risk of CVD in diabetes.

  65. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42(10):1589–600.

    PubMed  CAS  Google Scholar 

  66. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G: Haptoglobin and risk of myocardial infarction, stroke, and congestive heart failure in 342,125 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Annals of medicine 2009:1–11.

  67. • Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, Alshiek J, Bennett L, Kostenko M, Landau M et al: Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2–2 genotype: a prospective double-blinded clinical trial. Arteriosclerosis, thrombosis, and vascular biology 2008, 28(2):341–347. This prospective, placebo-controlled pharmacogenomic study showed that vitamin E provides significant cardiovascular protection to individuals with diabetes and the haptoglobin 2–2 genotype.

  68. Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, et al. Structure-function analysis of the antioxidant properties of haptoglobin. Blood. 2001;98(13):3693–8.

    Article  PubMed  CAS  Google Scholar 

  69. Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res. 2003;92(11):1193–200.

    Article  PubMed  CAS  Google Scholar 

  70. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res. 2005;96(4):435–41.

    Article  PubMed  CAS  Google Scholar 

  71. Timmermann M, Hogger P. Oxidative stress and 8-iso-prostaglandin F(2alpha) induce ectodomain shedding of CD163 and release of tumor necrosis factor-alpha from human monocytes. Free Radic Biol Med. 2005;39(1):98–107.

    Article  PubMed  CAS  Google Scholar 

  72. Boyle JJ, Harrington HA, Piper E, Elderfield K, Stark J, Landis RC, et al. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am J Pathol. 2009;174(3):1097–108.

    Article  PubMed  Google Scholar 

  73. Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, Asaf R, et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2–2 genotype. Diabetes. 2008;57(10):2794–800.

    Article  PubMed  CAS  Google Scholar 

  74. Farbstein D, Levy AP. Pharmacogenomics and the prevention of vascular complications in diabetes mellitus. Therapy. 2009;6(4):531–8.

    Article  CAS  Google Scholar 

  75. Pare G, Chasman DI, Parker AN, Zee RR, Malarstig A, Seedorf U, et al. Novel associations of CPS1, MUT, NOX4, and DPEP1 with plasma homocysteine in a healthy population: a genome-wide evaluation of 13 974 participants in the Women’s Genome Health Study. Circ Cardiovasc Genet. 2009;2(2):142–50.

    Article  PubMed  CAS  Google Scholar 

  76. O’Donnell CJ, Cupples LA, D’Agostino RB, Fox CS, Hoffmann U, Hwang SJ, Ingellson E, Liu C, Murabito JM, Polak JF et al: Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI’s Framingham Heart Study. BMC Med Genet 2007, 8 Suppl 1:S4.

    Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the Israel-US Binational Science Foundation, the Juvenile Diabetes Foundation, and the National Institutes of Health (NIH RO1DK085226).

Disclosure

All of the authors have received grants to their institution from the National Institutes of Health and the Juvenile Diabetes Research Foundation.

Author information

Authors and Affiliations

  1. The Ruth and Bruce Faculty of Medicine, Technion Israel Institute of Technology, Efron St., P.O.B. 9649, Haifa, 31096, Israel

    Dan Farbstein, Yitzchak Z. Soloveichik, Nina S. Levy & Andrew P. Levy

Authors
  1. Dan Farbstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yitzchak Z. Soloveichik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nina S. Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew P. Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dan Farbstein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Farbstein, D., Soloveichik, Y.Z., Levy, N.S. et al. Genetics of Redox Systems and Their Relationship with Cardiovascular Disease. Curr Atheroscler Rep 13, 215–224 (2011). https://doi.org/10.1007/s11883-011-0170-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-011-0170-7

Keywords

Search

Navigation